Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals, Inc.    ARWR

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Arrowhead Shares Up, Orion Group Falls After Hours on S&P SmallCap 600 Moves

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2019 | 08:05pm EDT

By Josh Beckerman

Arrowhead Pharmaceuticals shares rose 7% to $20.28 as the company was selected to join the S&P SmallCap 600, effective Friday.

Meanwhile, S&P Dow Jones Indices said is removing construction company Orion Group Holdings from the SmallCap 600, as it "has a market capitalization that is no longer representative of the small-cap market space."

Orion shares fell 4% to $2.23 after-hours.

Write to Josh Beckerman at josh.beckerman@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ARROWHEAD PHARMACEUTICALS, INC. -1.78% 35.95 Delayed Quote.189.45%
ORION GROUP HOLDINGS, INC. 3.04% 4.41 Delayed Quote.2.80%
S&P GLOBAL INC. -1.00% 250.48 Delayed Quote.48.88%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARROWHEAD PHARMACEUTICALS,
10/18ARROWHEAD PHARMACEUTICALS : Hosts R&D Day on Emerging Pipeline of RNAi Therapeut..
BU
10/02ARROWHEAD PHARMACEUTICALS : to Host R&D Day on Emerging Pipeline of RNAi Therape..
BU
09/30ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming October 2019 Conferences
BU
09/23ARROWHEAD PHARMACEUTICALS : Reports Inducement Grants under NASDAQ Marketplace R..
AQ
09/20ARROWHEAD PHARMACEUTICALS : Reports Inducement Grants under NASDAQ Marketplace R..
BU
09/16ARROWHEAD PHARMACEUTICALS : Presents Initial Top-Line Clinical Data and Preclini..
BU
09/02ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming September 2019 Conference..
AQ
08/30ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming September 2019 Conference..
BU
08/28ARROWHEAD PHARMACEUTICALS : Earns $25 Million Milestone in Janssen Collaboration
DJ
08/28ARROWHEAD PHARMACEUTICALS : Collaborator Janssen Begins REEF-1 Phase 2b Combinat..
BU
More news
Financials (USD)
Sales 2019 165 M
EBIT 2019 65,2 M
Net income 2019 71,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 49,5x
P/E ratio 2020 -117x
Capi. / Sales2019 20,7x
Capi. / Sales2020 41,8x
Capitalization 3 426 M
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 37,71  $
Last Close Price 35,95  $
Spread / Highest target 39,1%
Spread / Average Target 4,91%
Spread / Lowest Target -33,2%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Bruce D. Given Chief Operating Officer
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS, INC.189.45%3 426
GILEAD SCIENCES3.77%82 611
VERTEX PHARMACEUTICALS7.25%45 680
REGENERON PHARMACEUTICALS-19.63%32 998
WUXI APPTEC CO., LTD.68.13%20 570
GENMAB32.08%13 649